Artelo Biosciences, Inc. (ARTL) stock rose 15.77 percent to $5.14, gaining $0.70 on Monday, following the publication of new research supporting its non-opioid pain therapy approach.
The stock is currently trading at $5.14, compared to its previous close of $4.44 on the Nasdaq. During the session, it reached a high of $5.64 and a low of $4.79, with trading volume climbing to 29,255,913 shares, well above its average volume of 2,882,845.
The move comes after the company announced a peer-reviewed article highlighting FABP5 as a promising therapeutic target for pain management. Preclinical data showed consistent analgesic effects across multiple pain models, supporting the potential of its candidate ART26.12 as a novel, non-opioid treatment. Artelo Biosciences' 52-week range is $2.95 to $85.80.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.